Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The JointJYNT -1.22%63 Debt-to-Equity is 0.13 as of Mar. 2026, which is 83% below its 10-year median of 0.77. GuruFocus rates JYNT with a GF Score™ of 63/100 and a GF Value™ of $11.21 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 559 Healthcare Providers & Services companies, The Joint ranks better than 76.21% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for The Joint's Debt-to-Equity or its related term are showing as below:
JYNT'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.77 Max: 5.76
Current: 0.13
During the past 13 years, the highest Debt-to-Equity Ratio of The Joint was 5.76. The lowest was 0.03. And the median was 0.77.
JYNT's Debt-to-Equity is ranked better than 76.21% of 559
companies
in the Healthcare Providers & Services industry
Industry Median: 0.41
vs JYNT: 0.13
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
The Joint Debt-to-Equity Related Terms
The Joint Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for The Joint's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, The Joint's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
The Joint Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, The Joint's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where The Joint's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The Joint (JYNT) has a Debt-to-Equity of 0.13 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Joint and its competitors. This is 83% below median its historical median of 0.77. Over the past decade, The Joint's Debt-to-Equity has ranged from 0.03 to 5.76. According to the industry distribution chart, The Joint ranks #133 out of 559 companies in the Healthcare Providers & Services industry, placing it in the top 23.8%.
Is The Joint's Debt-to-Equity too high?
The Joint's current Debt-to-Equity of 0.13 is 83% below median its 10-year median of 0.77. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 5.76. The Healthcare Providers & Services industry median Debt-to-Equity is 0.41. The Joint's value of 0.13 is 68.3% below this industry median. Based on the distribution chart, The Joint ranks #133 out of 559 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, The Joint has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does The Joint's Debt-to-Equity compare to PARK and WW?
According to the Healthcare Providers & Services industry distribution chart, The Joint ranks #133 out of 559 companies for Debt-to-Equity. This places The Joint in the top 24% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.41. The Joint's value of 0.13 is 68.3% below this benchmark. Historically, The Joint's own Debt-to-Equity has ranged from 0.03 to 5.76 over the past decade. While the company's 10-year median is 0.77 vs. the industry median of 0.41, The Joint has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.41, based on 559 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. The Joint's current Debt-to-Equity of 0.13 is 68.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Joint and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Joint's current Debt-to-Equity is 0.13, which is 83% below median its own 10-year median of 0.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Joint stock overvalued right now?
Based on GuruFocus' analysis, The Joint (JYNT) is currently considered Modestly Undervalued. The stock's GF Value™ is $11.21, compared to a current price of $8.92 — trading 20.4% below its estimated fair value. The current Debt-to-Equity is 0.13, which is 83% below median its 10-year median of 0.77 and 68.3% below the Healthcare Providers & Services industry median of 0.41. The Joint's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For The Joint (JYNT), the current Debt-to-Equity is 0.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is The Joint (JYNT) Overvalued in 2026?
Based on GuruFocus' analysis, The Joint stock appears to be undervalued.
The current stock price of $8.92 is trading 20.4% below its estimated GF Value™ of $11.21.
GuruFocus considers The Joint to be Modestly Undervalued.
Key valuation signals for JYNT:
Debt-to-Equity: 0.13 (83% below median its 10-year median of 0.77)
GF Value™: $11.21 vs. price of $8.92 (20.4% below fair value)
Industry Position: 68.3% below the Healthcare Providers & Services median (#133 of 559)
No single metric tells the full story. See the JYNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
The Joint Corp develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and the sales of regional developer rights throughout the United States. The doctors of chiropractic develop personalized treatment plans to relieve patients' pain and deliver ongoing preventative care. The company has one operating business segment; The Franchise Operations segment, which is comprised of the operating activities of the franchise business unit. The Franchise Operations segment derives revenue from customers by providing access to the company's franchise license, which represents symbolic intellectual property.
63GF Score
Get the complete analysis for JYNT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JYNT has been successfully added to your 
